GlassScriptPhysician profile
Roger S Buck
NPI 1871593566
$2,256.17
in general payments reported to CMS, 2019-2025
22 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $260 · 2021: $240 · 2022: $355 · 2023: $369 · 2024: $456 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $597.24 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $287.86 | 2021-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $209.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.96 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $123.05 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.55 | 2019-2022 | |
| Exact Sciences Corporation | $99.44 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $93.68 | 2020-2023 | Mounjaro |
| Madrigal Pharmaceuticals | $84.20 | 2025 | Rezdiffra |
| Abbott Laboratories | $79.12 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $73.88 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $69.93 | 2020 | |
| Phathom Pharmaceuticals, INC. | $69.24 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $69.07 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.55 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.14 | 2019 | |
| Dexcom, INC. | $16.53 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.36 | 2020 | |
| Genentech USA, INC. | $14.42 | 2019 | |
| Sanofi Pasteur INC. | $11.37 | 2020 | |
| Vifor Pharma, INC. | $11.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.